Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India.
Given global Coronavirus Disease 2019 (COVID-19) vaccine shortages and inequity of vaccine distributions, fractionation of vaccine doses might be an effective strategy for reducing public health and economic burden, notwithstanding the emergence of new variants of concern. In this study, we developed a multi-scale model incorporating population-level transmission and individual-level vaccination to estimate the costs of hospitalization and vaccination and the economic benefits of reducing COVID-19 deaths due to dose-fractionation strategies in India. We used large-scale survey data of the willingness to pay together with data of vaccine and hospital admission costs to build the model. We found that fractional doses of vaccines could be an economically viable vaccination strategy compared to alternatives of either full-dose vaccination or no vaccination. Dose-sparing strategies could save a large number of lives, even with the emergence of new variants with higher transmissibility.
Funder: AIR@InnoHK administered by Innovation and Technology Commission, Hong Kong
Funder: The Engineering and Physical Sciences Research Council (EPSRC) Impact Acceleration Grant RG90413, and the International COVID-19 Data Alliance (ICODA), an initiative funded by the COVID-19 Therapeutics Accelerator and convened by Health Data Research UK.
Funder: the Collaborative Research Fund [Project No. C7123-20G] of the Research Grants Council of the Hong Kong SAR Government